Caladrius Biosciences (NASDAQ:CLBS) Upgraded at Zacks Investment Research


Share on StockTwits

Caladrius Biosciences (NASDAQ:CLBS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

Several other brokerages also recently weighed in on CLBS. Brookline Capital Management boosted their price target on Caladrius Biosciences from $7.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, March 9th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price target (down from $18.50) on shares of Caladrius Biosciences in a report on Tuesday, January 19th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $8.06.

Shares of Caladrius Biosciences stock traded down $0.04 during trading on Tuesday, hitting $1.58. 684,856 shares of the company were exchanged, compared to its average volume of 5,047,877. Caladrius Biosciences has a fifty-two week low of $1.25 and a fifty-two week high of $4.89. The stock has a market capitalization of $94.01 million, a price-to-earnings ratio of -2.47 and a beta of 1.55. The firm has a 50 day moving average price of $1.79 and a 200 day moving average price of $1.77.

Caladrius Biosciences (NASDAQ:CLBS) last issued its quarterly earnings results on Thursday, February 25th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.01). As a group, research analysts forecast that Caladrius Biosciences will post -1.54 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in CLBS. Renaissance Technologies LLC increased its holdings in shares of Caladrius Biosciences by 12.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,045,855 shares of the biotechnology company’s stock worth $1,496,000 after buying an additional 118,600 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Caladrius Biosciences during the 4th quarter worth $75,000. Squarepoint Ops LLC acquired a new stake in shares of Caladrius Biosciences during the 4th quarter worth $30,000. Finally, Game Plan Financial Advisors LLC acquired a new stake in shares of Caladrius Biosciences during the 1st quarter worth $29,000. Institutional investors and hedge funds own 8.99% of the company’s stock.

About Caladrius Biosciences

Caladrius Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.

Featured Article: How are capital gains distributions different for tax-deferred account?

Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.